GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Amcad Biomed Corp (ROCO:4188) » Definitions » Enterprise Value

Amcad Biomed (ROCO:4188) Enterprise Value : NT$560.32 Mil (As of May. 08, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Amcad Biomed Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Amcad Biomed's Enterprise Value is NT$560.32 Mil. Amcad Biomed's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was NT$-53.69 Mil. Therefore, Amcad Biomed's EV-to-EBIT ratio for today is -10.44.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Amcad Biomed's Enterprise Value is NT$560.32 Mil. Amcad Biomed's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was NT$-36.23 Mil. Therefore, Amcad Biomed's EV-to-EBITDA ratio for today is -15.47.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Amcad Biomed's Enterprise Value is NT$560.32 Mil. Amcad Biomed's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was NT$51.81 Mil. Therefore, Amcad Biomed's EV-to-Revenue ratio for today is 10.82.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Amcad Biomed's Enterprise Value is NT$560.32 Mil. Amcad Biomed's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was NT$-51.63 Mil. Therefore, Amcad Biomed's EV-to-FCF ratio for today is -10.85.


Amcad Biomed Enterprise Value Historical Data

The historical data trend for Amcad Biomed's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amcad Biomed Enterprise Value Chart

Amcad Biomed Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 733.96 769.46 623.73 1,246.54 1,155.72

Amcad Biomed Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,413.02 1,321.71 1,071.85 1,155.72 740.82

Competitive Comparison of Amcad Biomed's Enterprise Value

For the Medical Devices subindustry, Amcad Biomed's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amcad Biomed's Enterprise Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Amcad Biomed's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Amcad Biomed's Enterprise Value falls into.


;
;

Amcad Biomed Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Amcad Biomed's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as

Amcad Biomed's Enterprise Value for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amcad Biomed  (ROCO:4188) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Amcad Biomed's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=560.316/-53.685
=-10.44

Amcad Biomed's current Enterprise Value is NT$560.32 Mil.
Amcad Biomed's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-53.69 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Amcad Biomed's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=560.316/-36.228
=-15.47

Amcad Biomed's current Enterprise Value is NT$560.32 Mil.
Amcad Biomed's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-36.23 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Amcad Biomed's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=560.316/51.807
=10.82

Amcad Biomed's current Enterprise Value is NT$560.32 Mil.
Amcad Biomed's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$51.81 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Amcad Biomed's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=560.316/-51.631
=-10.85

Amcad Biomed's current Enterprise Value is NT$560.32 Mil.
Amcad Biomed's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-51.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amcad Biomed Enterprise Value Related Terms

Thank you for viewing the detailed overview of Amcad Biomed's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Amcad Biomed Business Description

Traded in Other Exchanges
N/A
Address
No. 167, Fuxing North Road, 5th Floor, Zhongshan District, Taipei, TWN, 104
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. The company's geographical segments include Taiwan, China, and other countries, out of which the majority of the revenue is generated from Europe. The company has two segments: Medical diagnostic software: which is responsible for the development and sales of smart medical imaging diagnostic software device and Precision medical equipment: which is responsible for research, development, manufacturing and sales of high-end ultrasonic probes.

Amcad Biomed Headlines

No Headlines